Covalent Modifiers

FEBRUARY 25, 2024

Herein, we used a targeted covalent inhibition strategy and identified a covalent inhibitor, TD19, which selectively inhibits ALKBH5 compared with FTO demethylase in protein-based and tumor cell-based assays. TD19 irreversibly modifies the residues C100 and C267, preventing ALKBH5 from binding to m6A-containing RNA.

RNA 157

RNA Cell Based Assays Regulations Research 157

Broad Institute

JUNE 30, 2023

Image analysis software captures information about more than 3,000 cellular features, providing a deep view into the impacts of genetic variants, small molecule or genetic perturbations, and more on cellular shape, structure, and function. “It moves the community from a very targeted, hypothesis-driven, unidimensional cell-based assay framework to (..)

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

Tebu Bio: Drug Discovery

APRIL 24, 2020

Recombinant monoclonal antibody (mAB) based treatments have proven their efficacy. Nevertheless, researchers are now considering using messenger RNA (mRNA) technologies for the development of prophylactic and therapeutic vaccines. HIV or more recently SARS-Cov-2). Pre-clinical and clinical trials […]

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

Broad Institute

JUNE 21, 2023

Cell Painting uses six fluorescent dyes to image eight different components of a cell: the nucleus, nucleoli, mitochondria, endoplasmic reticulum (ER), golgi apparatus, cytoplasmic RNA, f-actin cytoskeleton, and plasma membrane.

Small Molecule 52

Small Molecule Cell Based Assays Medical Schools Disease 52

Elrig

APRIL 29, 2024

She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures. Harini joined Serna Bio in early 2021 and has been an integral part of the multidisciplinary teamworking on target ID platform development to drug discovery.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59